Biased agonism

A pharmacological concept describing a ligand that activates one downstream signalling pathway of a receptor more strongly than another — central to the modern understanding of kratom’s safety profile.

Why it matters

When a ligand binds a G-protein-coupled receptor, two main downstream pathways can fire: the G-protein pathway (often associated with the therapeutic effect) and the beta-arrestin pathway (often associated with side effects like tolerance, dependence, and, for opioids, respiratory depression). A “biased” ligand preferentially activates one over the other. Mitragynine has been characterised as a biased mu-opioid agonist with stronger G-protein recruitment and weaker beta-arrestin recruitment.

In practice

In practice, biased agonism is the leading mechanistic explanation for why kratom’s overdose pharmacology looks different from classical opioids in epidemiological data — there is genuine pain relief without the same magnitude of respiratory depression. It is not, however, a license to treat kratom as risk-free.

Common confusion

Biased agonism is sometimes presented as making kratom “safer than opioids.” A more accurate framing is that mitragynine produces a different risk profile than classical opioids — different is not the same as safe.

This glossary entry is editorial content reviewed against primary sources. It is not medical advice. See our Editorial Policy.